快樂小藥師 Im pharmacist nichts glücklich

Rocephin與含鈣溶液的交互作用更新警告，重要！！

Audience: Neonatology, infectious disease healthcare professionals, hospital risk managers
[Posted 04/14/2009] FDA notified healthcare professionals of an update to a previous alert that addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates.

At the request of FDA, the manufacturer of ceftriaxone (Roche) conducted two in vitro studies to assess the potential for precipitation of ceftriaxone-calcium when ceftriaxone and calcium-containing products are mixed in vials and in infusion lines.

These two in vitro studies were conducted in neonatal and adult plasma to assess the potential for precipitation of ceftriaxone-calcium using varying ceftriaxone and calcium concentrations, including concentrations in excess of those achieved in vivo.

Based on the results from these studies,

FDA now recommends that ceftriaxone and

calcium-containing products may be used

concomitantly in patients >28 days of age,

using the precautionary recommendations

noted because the risk of precipitation is

low in this population.
 

（FDA現在建議如果病患為大於28天的人，由於Ceftriazone與含鈣溶液產生沈澱的風險較低，所以在此類族群可以並用。）

FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.

之前的警告在這邊：http://mulicia.pixnet.net/blog/post/5973760

關鍵字： ceftriazone rocephin Ca Calcium 羅氏芬 鈣 含鈣溶液